Clinical trial
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent…
NCT00344318 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00344318 |
|---|---|
| Title | Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine |
| Official title | To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Streptococcal |
| Intervention type | Biological |
| Interventions | Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Tritanrix-HepB, Hiberix, Polio Sabin., Poliorix. |
| Enrollment | 806 |
| Start date | Aug 7, 2006 |
| Primary completion | Apr 27, 2007 |
| Completion | Oct 17, 2007 |
| First posted | Jun 26, 2006 |
| Last update posted | Dec 7, 2018 |
| Countries | Philippines, Poland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: